Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study

Zacks06-11

Apellis Pharmaceuticals APLS announced positive data from the late-stage GALE long-term extension study evaluating its marketed drug, Syfovre (pegcetacoplan injection), to treat patients with ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2442313084?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/P_YBJxpMtPac37tw4WAE2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9752031dabc84079fccfebaf63c9eff9","is_english":true,"pubTime":"2024-06-11 21:48","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2442313084","market":"us","top_or_hot":-1,"title":"Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study","media":"Zacks","content":"<div>\n<p>Apellis Pharmaceuticals APLS announced positive data from the late-stage GALE long-term extension study evaluating its marketed drug, Syfovre (pegcetacoplan injection), to treat patients with ...</p>\n\n<a href=\"https://finance.yahoo.com/news/apellis-apls-upbeat-ga-data-134800446.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApellis (APLS) Up on Upbeat GA Data From Long-Term Syfovre Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-11 21:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/apellis-apls-upbeat-ga-data-134800446.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Apellis Pharmaceuticals APLS announced positive data from the late-stage GALE long-term extension study evaluating its marketed drug, Syfovre (pegcetacoplan injection), to treat patients with ...</p>\n\n<a href=\"https://finance.yahoo.com/news/apellis-apls-upbeat-ga-data-134800446.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALXO","symbol_name":"ALX Oncology Holdings","start_time":0,"source_url":"https://finance.yahoo.com/news/apellis-apls-upbeat-ga-data-134800446.html","article_id":"2442313084","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/P_YBJxpMtPac37tw4WAE2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9752031dabc84079fccfebaf63c9eff9"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2442313084","pubTimestamp":1718113680,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Per the data readout, presented at a recent medical conference, treatment with Syfovre in the GALE study preserved visual function at 36 months in the GA patients. Per Apellis, Syfovre is the only approved GA treatment to show a benefit on visual function in a prespecified endpoint.Additionally, it was observed that patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month Syfovre treatment compared with patients from the sham crossover group, which met a prespecified microperimetry endpoint.The phase III GALE extension study mostly enrolled patients who completed the late-stage OAKS and DERBY studies, positive results from which supported the approval of Syfovre for the GA indication.The drug has witnessed robust initial uptake since its commercial launch in March 2023.Syfovre recorded sales of $137.5 million in the first quarter of 2024, which increased 20.3% sequentially, owing to continued strong demand, thereby driving revenues","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALXO":"ALX Oncology Holdings","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","ANVS":"Annovis Bio, Inc.","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","APLS":"Apellis Pharmaceuticals Inc.","BK4121":"生命科学工具和服务","CGEN":"Compugen医疗","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4588":"碎股","BK4505":"高瓴资本持仓"},"translate_title":"Apellis(APLS)因Syfovre长期研究的乐观GA数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALXO":1,"ANVS":1,"APLS":1,"CGEN":1},"content_text":"Apellis Pharmaceuticals APLS announced positive data from the late-stage GALE long-term extension study evaluating its marketed drug, Syfovre (pegcetacoplan injection), to treat patients with geographic atrophy (GA) secondary to age-related macular degeneration.\nPer the data readout, presented at a recent medical conference, treatment with Syfovre in the GALE study preserved visual function at 36 months in the GA patients. Per Apellis, Syfovre is the only approved GA treatment to show a benefit on visual function in a prespecified endpoint.\nAdditionally, it was observed that patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month Syfovre treatment compared with patients from the sham crossover group, which met a prespecified microperimetry endpoint.\nPlease note that scotomatous points measure areas of the retina that have lost all light sensitivity and, therefore, are no longer functioning.\nThe stock gained 3.3% on Monday, Jun 10, in response to the positive GALE study data. Year to date, Apellis’ shares plunged 30.3% compared with the industry’s 5.9% decline.\nImage Source: Zacks Investment Research\nThe phase III GALE extension study mostly enrolled patients who completed the late-stage OAKS and DERBY studies, positive results from which supported the approval of Syfovre for the GA indication.\nPatients in the sham crossover group completed treatment with sham injections from months 0-24 in the phase III OAKS study and received Syfovre from months 24-36. Microperimetry was a key secondary endpoint measured only in the OAKS study, and therefore, patients who crossed over from the OAKS study were included in the long-term extension study.\nSyfovre received FDA approval in February 2023 for the GA indication. It has the potential to be a best-in-class treatment for patients with GA, a disease that is the leading cause of blindness, affecting more than one million people in the United States and five million people worldwide.\nThe drug has witnessed robust initial uptake since its commercial launch in March 2023.Syfovre recorded sales of $137.5 million in the first quarter of 2024, which increased 20.3% sequentially, owing to continued strong demand, thereby driving revenues for the company. Apellis delivered more than 72,000 commercial vials and nearly 5,000 samples of Syfovre to doctors in the first quarter. As of Mar 31, 2024, the total number of drug doses delivered since launch was 250,000.\nA marketing authorization application seeking approval of intravitreal pegcetacoplan to treat GA is currently under review in the EU and several other countries. A decision from the European Medicines Agency is expected no later than July 2024. Approvals from regulatory bodies in other countries are also expected in the current year.Potential approval of the drug in additional geographies will further boost the top line.\nApellis also currently markets pegcetacoplan under the brand name Empaveli/Aspaveli in the United States and EU, as a monotherapy treatment for adult patients suffering from paroxysmal nocturnal hemoglobinuria. The drug is also approved in several other geographies for the same indication.\n\nApellis Pharmaceuticals, Inc. Price and Consensus\n\nApellis Pharmaceuticals, Inc. price-consensus-chart | Apellis Pharmaceuticals, Inc. Quote\n\nZacks Rank and Stocks to Consider\nApellis currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks from the drug/biotech industry are ALX Oncology Holdings ALXO, Annovis Bio ANVS and Compugen CGEN, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nIn the past 30 days, the Zacks Consensus Estimate for ALX Oncology’s 2024 loss per share has narrowed from $3.33 to $2.89. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.85 to $2.73. Year to date, shares of ALXO have plunged 41.8%.\nALX Oncology beat estimates in two of the trailing four quarters and missed twice, delivering an average negative surprise of 8.83%.\nIn the past 30 days, the Zacks Consensus Estimate for Annovis’ 2024 loss per share has narrowed from $2.93 to $2.46. During the same period, the consensus estimate for 2025 loss per share has narrowed from $2.83 to $1.95. Year to date, shares of ANVS have plunged 65.2%.\nANVS beat estimates in three of the trailing four quarters and missed once, delivering an average negative surprise of 1.39%.\nIn the past 30 days, the Zacks Consensus Estimate for Compugen’s 2024 earnings per share has increased from 2 cents to 5 cents. The consensus estimate for 2025 loss per share is currently pegged at 11 cents. Year to date, shares of CGEN have gained 2.5%.\nCGEN’s earnings beat estimates in three of the trailing four quarters and missed once, delivering an average surprise of 5.79%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nCompugen Ltd. (CGEN) : Free Stock Analysis Report\nApellis Pharmaceuticals, Inc. (APLS) : Free Stock Analysis Report\nAnnovis Bio, Inc. (ANVS) : Free Stock Analysis Report\nALX Oncology Holdings Inc. (ALXO) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2442313084"}